Literature DB >> 9571181

Human pigmentation phenotype: a point mutation generates nonfunctional MSH receptor.

P A Frändberg1, M Doufexis, S Kapas, V Chhájlani.   

Abstract

alpha-Melanocyte stimulating hormone (alpha-MSH) regulates skin and hair pigmentation by modulating the activity of MSH receptor (MC1R). We have identified Arg151Cys variant of human MC1R in genomic DNA isolated from a person with red hair and light skin of type I. The Arg151Cys variant of MC1R binds to radio-labelled analogue of alpha-MSH with identical affinity as wild type MC1R but can not be stimulated to produce cyclic AMP (cAMP). The mutation Arg151Cys renders human MC1R completely nonfunctional, which explains the red hair, light skin and poor tanning ability (skin type I). This is the first report ever describing a nonfunctional MC1R isolated from a human subject.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9571181     DOI: 10.1006/bbrc.1998.8459

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma.

Authors:  P A van der Velden; L A Sandkuijl; W Bergman; S Pavel; L van Mourik; R R Frants; N A Gruis
Journal:  Am J Hum Genet       Date:  2001-08-07       Impact factor: 11.025

2.  Influence of oligomerization on the dynamics of G-protein coupled receptors as assessed by normal mode analysis.

Authors:  Masha Y Niv; Marta Filizola
Journal:  Proteins       Date:  2008-05-01

Review 3.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

4.  Pharmacological and functional characterization of the guinea-pig B2 bradykinin receptor stably expressed in CHO-K1 cell line.

Authors:  C Robert; D Pruneau; J-L Paquet
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  cAMP-independent non-pigmentary actions of variant melanocortin 1 receptor: AKT-mediated activation of protective responses to oxidative DNA damage.

Authors:  María Castejón-Griñán; Cecilia Herraiz; Conchi Olivares; Celia Jiménez-Cervantes; Jose Carlos García-Borrón
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

6.  A high-coverage genome sequence from an archaic Denisovan individual.

Authors:  Matthias Meyer; Martin Kircher; Marie-Theres Gansauge; Heng Li; Fernando Racimo; Swapan Mallick; Joshua G Schraiber; Flora Jay; Kay Prüfer; Cesare de Filippo; Peter H Sudmant; Can Alkan; Qiaomei Fu; Ron Do; Nadin Rohland; Arti Tandon; Michael Siebauer; Richard E Green; Katarzyna Bryc; Adrian W Briggs; Udo Stenzel; Jesse Dabney; Jay Shendure; Jacob Kitzman; Michael F Hammer; Michael V Shunkov; Anatoli P Derevianko; Nick Patterson; Aida M Andrés; Evan E Eichler; Montgomery Slatkin; David Reich; Janet Kelso; Svante Pääbo
Journal:  Science       Date:  2012-08-30       Impact factor: 47.728

7.  Evidence for variable selective pressures at MC1R.

Authors:  R M Harding; E Healy; A J Ray; N S Ellis; N Flanagan; C Todd; C Dixon; A Sajantila; I J Jackson; M A Birch-Machin; J L Rees
Journal:  Am J Hum Genet       Date:  2000-03-24       Impact factor: 11.025

Review 8.  MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.

Authors:  Jose C García-Borrón; Zalfa Abdel-Malek; Celia Jiménez-Cervantes
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-30       Impact factor: 4.693

9.  Genetic counseling in melanoma.

Authors:  Celia Badenas; Paula Aguilera; Joan A Puig-Butillé; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  Dermatol Ther       Date:  2012 Sep-Oct       Impact factor: 2.851

10.  MC1R mutations modify the classic phenotype of oculocutaneous albinism type 2 (OCA2).

Authors:  Richard A King; Rebecca K Willaert; Ramona M Schmidt; Jacy Pietsch; Sarah Savage; Marcia J Brott; James P Fryer; C Gail Summers; William S Oetting
Journal:  Am J Hum Genet       Date:  2003-07-22       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.